ClinicalTrials.gg
TerminatedNCT04093427Updated Dec 21, 2023

Influence of an Inverse Pressure Ramp in Long-term Non-invasive Ventilation on Dyspnea in the Morning After Therapy

An interventional study of softSTOPP in Noninvasive Ventilation and Dyspnea, sponsored by Wissenschaftliches Institut Bethanien e.V. Terminated at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-21.

Sponsored by Wissenschaftliches Institut Bethanien e.V · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Insufficient recruitment in a timely manner

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Dyspnea with a site in Germany — 1 open to participants now, 3 under way, none of them phase 3. Dyspnea · Germany.

Enrollment
18th of 20
8 · median 178
Started
2019
with 1 other
No phase
6 of 31
none open now
Registered
28th of 31
by date

Among the 31 studies in Dyspnea with a site in Germany, this one is the 18th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2019, is one of 6 with no phase, and was the 28th registered.

Dyspnea

895 studies on the registry are indexed under Dyspnea; 189 are open to participants now.

Browse Dyspnea studies →

Open to participants now

1 of the 31 studies in Dyspnea with a site in Germany is open now. Recruiting first, the newest first:

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 125 Dyspnea studies recruiting now, 68 (54%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Dyspnea with a site in Germany, or all of them as a file.
02

Study summary

Patients being treated with non-invasive home mechanical ventilation (NIV) may experience morning dyspnea after each night of NIV use, when the therapy is abruptly ended. This study aims to show that dyspnea intensity can be significantly reduced by a gentle NIV therapy end, delivered by a continuously decreasing pressure level (inverse pressure ramp) after therapy end in the morning, a feature called softSTOPP, which can configured in prismaVENT NIV devices. This could also improve therapy adherence.

03

Conditions studied

  • Noninvasive Ventilation
  • Dyspnea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Diagnosis of a (COPD) with chronic hypercapnic insufficiency
  • Therapy with prismaVENT 30, firmware V 3.3 or higher, mode S/T, stable device settings at the time of inclusion without need to adapt ventilation parameters
  • May have co-existing obstructive sleep apnea syndrome
  • Subjective dyspnea ≥3 (Borg scale) after end of ventilation therapy in the morning
  • Written for study participation including data protection

Exclusion criteria

Exclusion Criteria:

  • Missing written for study participation including data protection
  • for positive airway pressure therapy
  • Use of the softSTOPP feature before study inclusion
  • Participation in another study, which influences NIV therapy by defining device settings or titration
  • Concomitant oxygen therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Active comparator
    softSTOPP active

    Other: softSTOPP

  • No intervention
    softSTOPP inactive

Interventions

  • OthersoftSTOPP

    Non-invasive ventilation device setting in prismaVENT 30 device enabling an inverse pressure ramp after therapy end

06

What researchers measure

Primary outcomes

  1. Change of dyspnea level from baseline to 12 weeks

    Delta value of morning dyspnea from baseline to 12 weeks as measured by the Borg Scale. The Borg Scale ranges from 0 (no perceived dyspnea at all) to 10 (maximum perceived dyspnea).

    Time frame: 12 weeks

07

Study locations

1 site
  • Krankenhaus Bethanien
    Solingen, NRW 42699, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Jul 2022, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2019
First posted
Sep 18, 2019
StartActual
Aug 1, 2019
Primary completionActual
Jul 31, 2022
CompletionActual
Jul 31, 2022
Last update
Dec 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04093427
Lead sponsor
Wissenschaftliches Institut Bethanien e.V
Collaborators
Löwenstein Medical Technology GmbH & Co. KG
Responsible party
Sponsor
First posted
Sep 18, 2019
Start date
Aug 1, 2019
Primary completion
Jul 31, 2022
Completion
Jul 31, 2022
Last update
Dec 21, 2023

Study contacts

Winfried J Randerath, Prof. Dr.
principal investigator · Krankenhaus Bethanien

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion